Form 8-K - Current report:
SEC Accession No. 0001576885-25-000072
Filing Date
2025-06-05
Accepted
2025-06-05 16:37:03
Documents
12
Period of Report
2025-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K abos-20250604.htm   iXBRL 8-K 33235
  Complete submission text file 0001576885-25-000072.txt   156382

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20250604.xsd EX-101.SCH 1782
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20250604_lab.xml EX-101.LAB 23449
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20250604_pre.xml EX-101.PRE 13581
15 EXTRACTED XBRL INSTANCE DOCUMENT abos-20250604_htm.xml XML 3345
Mailing Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465
Business Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465 617-344-4190
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 251027661
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)